Biocon Gets A New Group CEO As Aflibercept Approval Arrives
Peter Bains Named As New Chief; Yesafili Biosimilar Is Europe’s First Eylea Rival
Biocon has named Peter Bains as its new group CEO, as the firm’s Biocon Biologics business confirmed that its aflibercept biosimilar to Eylea had become the first to receive a formal European approval.
You may also be interested in...
Formycon has submitted its aflibercept candidate for European Medicines Agency consideration, following an incredibly strong Q3 which has put the company on track for a promising future.
API giant Euroapi is looking for new leadership after its board decided that CEO Karl Rotthier would step down from the role. Meanwhile, Biocon Biologics has named a new chief financial officer and Perrigo has announced a management change.
Biocon Biologics has announced the latest milestone in its integration of former partner Viatris’s biosimilars business, completing the move in the US and Canada “ahead of schedule.”